Replies to post #209735 on Biotech Values

[WorstLuck]

• In such therapeutic indications as cervical dystonia, where the typical dose is 5-10x higher than in cosmetic indications, some Botox patients develop neutralizing antibodies, rendering subsequent treatment ineffective. RT002’s smaller molecular footprint compared to other botulinum toxins makes it less immunogenic, and no RT002 patients have experienced neutralizing antibodies in any clinical trials to date.

I see reports of neutralizing antibodies in aesthetic application too.

https://doi.org/10.2147/CCID.S51938

...The case studies presented in this report show that neutralizing antibodies can occur even with the low doses of botulinum toxin type A used in aesthetic practice and may result in secondary treatment failure. ...

An immune response rate that is sufficiently lower than the competition will pay dividends down the road if it is demonstrable. I don't see value right now. I also don't see value to the 'yuck factor' if they are already willing to be injected with a botulism toxin.

What would be interesting to know is if 002 is enough different from other strains to be able to treat some number of treatment failures from those strains.